scholarly journals Delivery of drugs into brain tumors using multicomponent silica nanoparticles

Nanoscale ◽  
2019 ◽  
Vol 11 (24) ◽  
pp. 11910-11921 ◽  
Author(s):  
O. Turan ◽  
P. Bielecki ◽  
V. Perera ◽  
M. Lorkowski ◽  
G. Covarrubias ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Brain Tumors ◽  
Silica Nanoparticles ◽  
Radiofrequency Field

After targeting the nanoparticle to brain tumors, widespread drug delivery to the entire tumor is triggered by a radiofrequency field.

Recent Advances in Application of Azobenzenes Grafted on Mesoporous Silica Nanoparticles in Controlled Drug Delivery Systems Using Light as External Stimulus

2020 ◽  
Vol 20 (11) ◽  
pp. 1001-1016
Author(s):  
Sandra Ramírez-Rave ◽  
María Josefa Bernad-Bernad ◽  
Jesús Gracia-Mora ◽  
Anatoly K. Yatsimirsky
Keyword(s):  
Drug Delivery ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Drug Delivery Systems ◽  
Mesoporous Silica Nanoparticles ◽  
High Surface ◽  
Delivery Systems ◽  
Surface Reactivity ◽  
External Stimulus ◽  
Recent Advances

Hybrid materials based on Mesoporous Silica Nanoparticles (MSN) have attracted plentiful attention due to the versatility of their chemistry, and the field of Drug Delivery Systems (DDS) is not an exception. MSN present desirable biocompatibility, high surface area values, and a well-studied surface reactivity for tailoring a vast diversity of chemical moieties. Particularly important for DDS applications is the use of external stimuli for drug release. In this context, light is an exceptional alternative due to its high degree of spatiotemporal precision and non-invasive character, and a large number of promising DDS based on photoswitchable properties of azobenzenes have been recently reported. This review covers the recent advances in design of DDS using light as an external stimulus mostly based on literature published within last years with an emphasis on usually overlooked underlying chemistry, photophysical properties, and supramolecular complexation of azobenzenes.

scholarly journals Focused ultrasound in neuro-oncology: the role of the Focused Ultrasound Foundation in driving adoption and innovation

2021 ◽  
Author(s):  
Emily C. Whipple ◽  
Camille A. Favero ◽  
Neal F. Kassell
Keyword(s):  
Drug Delivery ◽  
Brain Tumors ◽  
Focused Ultrasound ◽  
Clinical Evidence ◽  
Neurological Injury ◽  
High Concentration ◽  
Potential Applications ◽  
Tumor Agent

Abstract Introduction Intra-arterial (lA) delivery of therapeutic agents across the blood-brain barrier (BBB) is an evolving strategy which enables the distribution of high concentration therapeutics through a targeted vascular territory, while potentially limiting systemic toxicity. Studies have demonstrated lA methods to be safe and efficacious for a variety of therapeutics. However, further characterization of the clinical efficacy of lA therapy for the treatment of brain tumors and refinement of its potential applications are necessary. Methods We have reviewed the preclinical and clinical evidence supporting superselective intraarterial cerebral infusion (SSJACI) with BBB disruption for the treatment of brain tumors. In addition, we review ongoing clinical trials expanding the applicability and investigating the efficacy of lA therapy for the treatment of brain tumors. Results Trends in recent studies have embraced the use of SSIACI and less neurotoxic chemotherapies. The majority of trials continue to use mannitol as the preferred method of hyperosmolar BBB disruption. Recent preclinical and preliminary human investigations into the lA delivery of Bevacizumab have demonstrated its safety and efficacy as an anti-tumor agent both alone and in combination with chemotherapy. Conclusion lA drug delivery may significantly affect the way treatment are delivered to patients with brain tumors, and in particular GBM. With refinement and standardization of the techniques of lA drug delivery, improved drug selection and formulations, and the development of methods to minimize treatment-related neurological injury, lA therapy may offer significant benefits for the treatment of brain tumors.

Pollen-like silica nanoparticles as a nanocarrier for tumor targeted and pH-responsive drug delivery

Talanta ◽  
2021 ◽  
Vol 231 ◽  
pp. 122402
Author(s):  
Rongrong Jin ◽  
Jiaxi Wang ◽  
Mingxia Gao ◽  
Xiangmin Zhang
Keyword(s):  
Drug Delivery ◽  
Silica Nanoparticles ◽  
Ph Responsive

Wetting transition in nanochannels for biomimetic free-blocking on-demand drug transport

2018 ◽  
Vol 6 (39) ◽  
pp. 6269-6277 ◽  
Author(s):  
Yaya Cheng ◽  
Xiangyu Jiao ◽  
Liang Zhao ◽  
Yang Liu ◽  
Fang Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Drug Delivery System ◽  
Delivery System ◽  
Drug Transport ◽  
Mesoporous Silica Nanoparticles ◽  
Wetting Transition ◽  
On Demand ◽  
Inner Surface

Inspired by aquaporins in nature, herein, a biomimetic free-blocking on-demand drug delivery system is proposed, which is constructed by controlling the wettability of the inner surface of nanochannels on mesoporous silica nanoparticles (MSNs).

scholarly journals ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3321
Author(s):  
Etienne J. Slapak ◽  
Lily Kong ◽  
Mouad el Mandili ◽  
Rienk Nieuwland ◽  
Alexander Kros ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Conditioned Medium ◽  
Drug Delivery System ◽  
Delivery System ◽  
Targeted Drug Delivery ◽  
Mesoporous Silica Nanoparticles ◽  
Pdac Cell ◽  
Targeted Drug

Pancreatic ductal adenocarcinoma (PDAC) has the worst survival rate of all cancers. This poor prognosis results from the lack of efficient systemic treatment regimens, demanding high-dose chemotherapy that causes severe side effects. To overcome dose-dependent toxicities, we explored the efficacy of targeted drug delivery using a protease-dependent drug-release system. To this end, we developed a PDAC-specific drug delivery system based on mesoporous silica nanoparticles (MSN) functionalized with an avidin–biotin gatekeeper system containing a protease linker that is specifically cleaved by tumor cells. Bioinformatic analysis identified ADAM9 as a PDAC-enriched protease, and PDAC cell-derived conditioned medium efficiently cleaved protease linkers containing ADAM9 substrates. Cleavage was PDAC specific as conditioned medium from leukocytes was unable to cleave the ADAM9 substrate. Protease linker-functionalized MSNs were efficiently capped with avidin, and cap removal was confirmed to occur in the presence of PDAC cell-derived ADAM9. Subsequent treatment of PDAC cells in vitro with paclitaxel-loaded MSNs indeed showed high cytotoxicity, whereas no cell death was observed in white blood cell-derived cell lines, confirming efficacy of the nanoparticle-mediated drug delivery system. Taken together, this research introduces a novel ADAM9-responsive, protease-dependent, drug delivery system for PDAC as a promising tool to reduce the cytotoxicity of systemic chemotherapy.

139 POSTER Enhanced drug delivery to brain tumors with a new paclitaxel-peptide conjugate

2008 ◽  
Vol 6 (12) ◽  
pp. 45 ◽  
Author(s):  
F. Bichat ◽  
M. Demeule ◽  
B. Lawrence ◽  
O. Raguin ◽  
B. Sourzat ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Brain Tumors
Sign in / Sign up

Export Citation Format

Share Document